LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (OTCBB:IMUC)(IMUC), a biotechnology company, announced the issuance of a U.S. patent relating to the company’s monoclonal antibody therapeutics. Patent No. 7,498,129 entitled “Myeloma Cell and Ovarian Cancer Cell Surface Glycoproteins, Antibodies Thereto, and Uses Thereof,” covers the use of IMUC’s antibodies to measure the effectiveness of the company’s proposed treatment of multiple myeloma and ovarian cancer using the company’s proprietary molecular antibodies. This builds on IMUC’s existing patent portfolio covering technologies for both the detection and the treatment of multiple types of cancer.
